This is a StreetInsider.com Premium Only Page

(CFBI) – StreetInsider.com Reports

Dec 28, 2022 07:01 AM Can-Fite BioPharma (CANF) Announces Namodenoson Increases Survival for the Most Severe Patients with Advanced Liver Cancer

Aug 17, 2022 07:26 AM Can-Fite BioPharma (CANF) Reports Progress in the Development of Piclidenoson for Osteoarthritis in Pets Through its Partner Vetbiolix

Jul 11, 2022 07:01 AM Can-Fite BioPharma (CANF) to Submit FDA & EMA Registration Plans for Piclidenoson in the Oral Treatment of Moderate to Severe Psoriasis

Jun 9, 2022 07:01 AM Can-Fite BioPharma (CANF) Announces Publication of Clinical Study Data for Piclidenoson and Namodenoson in Scientific Journal

Mar 14, 2022 07:02 AM Can-Fite BioPharma (CANF) Announces Namodenoson’s Treatment of Liver Fibrosis Receives Notice of Allowance from U.S. Patent Office

Dec 20, 2021 07:04 AM Can-Fite BioPharma (CANF) Announces Liver Cancer Patient Treated with its Namodenoson Clears All Cancer Lesions Under Open Label Extension of Phase II Study

Dec 7, 2021 07:06 AM Can-Fite BioPharma (CANF) Phase III Psoriasis Study to Complete 16-Week Treatment of Last Patient in January; Topline Data Expected Q1 2022

Nov 1, 2021 07:01 AM Can-Fite BioPharma (CANF) Findings on Cannabis Compound’s Inhibition of Liver Cancer are Published in HEPATOLOGY and will be Presented at the AASLD

Oct 28, 2021 07:22 AM Can-Fite BioPharma (CANF) NASH Patents Granted and Allowed in Japan, Hong Kong, and Mexico

Jul 8, 2021 07:10 AM Can-Fite BioPharma (CANF) Gears Up to Initiate Pivotal Phase III Liver Cancer Study

Jun 28, 2021 07:10 AM Can-Fite BioPharma (CANF) Enters Projected $3 Billion Veterinary Osteoarthritis Market: Signs Agreement with Vetbiolix for Development of Piclidenoson for Pets

Jun 16, 2021 07:45 AM Can-Fite BioPharma (CANF) Receives Notice of Patent Allowance in China for NASH Treatment

Jun 2, 2021 07:36 AM Can-Fite BioPharma (CANF) Initiate Phase IIb NASH Study in Isreal

Apr 29, 2021 07:46 AM Can-Fite BioPharma (CANF) Phase III Psoriasis Study Achieves 75% Enrollment; Top Line Results Expected Q4 2021

Apr 22, 2021 07:21 AM Can-Fite BioPharma (CANF) Expands its Phase II COVID-19 Study to Europe

Apr 5, 2021 07:08 AM Can-Fite BioPharma (CANF) Announces Cannabis Compound Inhibits Liver Cancer Growth in Preclinical Studies

Mar 30, 2021 08:07 AM Can-Fite BioPharma (CANF) Announces Summary of Existing Out-licensing Deals with Potential Milestone Payments of up to approximately $130 million

Mar 18, 2021 07:18 AM Can-Fite BioPharma (CANF) Announces Topical Administration of CF602 Fully Recovers Erectile Dysfunction in Diabetic Model

Mar 16, 2021 07:06 AM Can-Fite BioPharma (CANF) Signs $42.7 Million Out-Licensing Deal with Ewopharma

Mar 5, 2021 07:03 AM Can-Fite BioPharma (CANF) Enrolls First Patient in Phase II COVID-19 Study Under FDA Protocol

Feb 22, 2021 07:11 AM Can-Fite BioPharma (CANF) New Positive Data from its Liver Cancer Phase II Clinical Study with Namodenoson

Jan 8, 2021 07:08 AM Can-Fite BioPharma (CANF) Announces Publication of Namodenoson Liver Cancer Study in Peer Reviewed Journal—Cancers

Dec 14, 2020 07:03 AM Can-Fite BioPharma (CANF) Reports on Progress With Its Namodenoson NASH Program

Nov 24, 2020 07:05 AM Can-Fite BioPharma (CANF) Namodenoson Abstract Selected as ‘Best of The Liver Meeting’ in the NASH Category of AASLD

Nov 23, 2020 09:03 AM Community First Bancshares Inc. (CFBI) Announces Commencement of Stock Offering

Nov 16, 2020 07:07 AM Can-Fite BioPharma (CANF) Presented NASH Phase II Namodenoson Data at Late Breaking Session of AASLD Conference

Oct 6, 2020 07:35 AM Can-Fite BioPharma (CANF) Announces Positive Phase III Psoriasis Interim Data Analysis

Sep 30, 2020 07:02 AM Can-Fite BioPharma (CANF) to Deliver Late-Breaking Oral Presentation on Namodenoson’s Treatment of NASH at AASLD

Sep 9, 2020 09:05 AM Community First Bancshares (CFBI) Announces Adoption of Plan of Conversion for Second-Step Stock Offering

Aug 31, 2020 07:06 AM Can-Fite BioPharma (CANF) Announces FDA Clears Can-Fite to Commence Phase II COVID-19 Study

Aug 25, 2020 08:11 AM Can-Fite BioPharma (CANF) Receives Notification of Patent Grant from European Patent Office for Namodenoson in Treatment of NASH

Jul 20, 2020 07:03 AM Can-Fite BioPharma (CANF) Completes Development of an Assay to Identify Clinically Active Cannabis Derived Compounds

Jul 15, 2020 07:01 AM Can-Fite BioPharma (CANF) Completes Phase II COVID-19 Protocol Based on FDA Guidance, Plans to File IND Shortly

Jun 30, 2020 07:01 AM Can-Fite BioPharma (CANF) Reports Final Data Analysis from Phase II NASH Study Demonstrates Highly Significant & Sustained Reduction in Liver Fat Volume Throughout Study Period

Jun 9, 2020 07:02 AM Can-Fite BioPharma (CANF) Announces, Following Pre-IND Guidance from FDA, to Advance Piclidenoson into Phase II COVID-19 Trial in the U.S.

Jun 4, 2020 07:15 AM Can-Fite BioPharma (CANF) Concludes Successful Meeting with EMA Regarding Phase III Trial and Registration Plan for Namodenoson in Treatment of Liver Cancer

May 21, 2020 07:11 AM Can-Fite BioPharma (CANF) Receives Notice of Allowance for Namodenoson Patent in Treatment of NASH & NAFLD from U.S. PTO

Apr 13, 2020 06:30 AM Can-Fite BioPharma (CANF) Received Approval for COVID-19 Clinical Trial in Israel, Patient Enrollment and Dosing to Commence Immediately

Apr 7, 2020 09:02 AM Can-Fite BioPharma (CANF) Announces Positive Top Line Results from its Phase II NASH Study with Namodenoson

Mar 30, 2020 07:04 AM Can-Fite BioPharma (CANF) Implements Interim Analysis for its Phase III Psoriasis Trial with Data Expected Q4 2020

Mar 23, 2020 07:45 AM Can-Fite BioPharma (CANF) Announces Piclidenoson is Submitted for Compassionate Use Treatment for Coronavirus Patients in Israel

Mar 13, 2020 07:07 AM Can-Fite (CANF) to Explore the anti-Coronavirus Effects of Piclidenoson in Collaboration with Lewis Katz School of Medicine at Temple University

Feb 10, 2020 02:49 PM Can-Fite BioPharma (CANF) Announces Pricing of $5 Million Public Offering of ADSs, Warrants

Jan 16, 2020 07:05 AM Can-Fite BioPharma (CANF), Univo Pharmaceuticals Collaboration Result in Discovery and Applied Patent for Cannabinoid Formulations

Jan 7, 2020 08:22 AM Can-Fite BioPharma (CANF) announces Data from Phase II Liver Cancer Study with Namodenoson will be presented at the ISCORT Conference

Jan 6, 2020 07:01 AM Can-Fite BioPharma (CANF) CEO Issues Letter to Shareholders

Jan 3, 2020 07:07 AM Can-Fite BioPharma (CANF) Announces New Data From Hadassah Medical Center Lab Show its Namodenoson Induces Weight Loss

Oct 31, 2019 08:16 AM Can-Fite BioPharma (CANF) Announces FDA Agreed with its Proposed Pivotal Phase III Trial Design to Support NDA Submission and Approval of Namodenoson in Treatment of Liver Cancer

Aug 20, 2019 01:13 PM Community First Bancshares Inc. (CFBI) Announces Merger Agreement to Acquire ABB Financial Group, Inc.

May 20, 2019 02:08 PM Can-Fite BioPharma (CANF) Announces $6 Million Registered Direct Offering of ADSs, Warrants